TransMedics Group, Inc. (NASDAQ:TMDX) Shares Bought by Farther Finance Advisors LLC

Farther Finance Advisors LLC grew its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 187.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 485 shares of the company’s stock after buying an additional 316 shares during the period. Farther Finance Advisors LLC’s holdings in TransMedics Group were worth $76,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. International Assets Investment Management LLC purchased a new stake in TransMedics Group during the 2nd quarter worth about $47,000. USA Financial Formulas purchased a new stake in shares of TransMedics Group during the third quarter worth about $55,000. J.Safra Asset Management Corp raised its position in shares of TransMedics Group by 649.2% in the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after buying an additional 383 shares during the last quarter. Signaturefd LLC lifted its stake in shares of TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after buying an additional 93 shares during the period. Finally, Amalgamated Bank boosted its position in TransMedics Group by 6.7% during the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after acquiring an additional 70 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Up 2.6 %

Shares of TMDX stock opened at $91.41 on Wednesday. TransMedics Group, Inc. has a fifty-two week low of $56.83 and a fifty-two week high of $177.37. The firm’s 50 day moving average price is $130.45 and its two-hundred day moving average price is $139.89. The stock has a market cap of $3.07 billion, a price-to-earnings ratio of 101.04 and a beta of 2.08. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. During the same period in the previous year, the firm posted ($0.12) earnings per share. The company’s revenue for the quarter was up 63.7% on a year-over-year basis. On average, analysts anticipate that TransMedics Group, Inc. will post 1.07 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on TMDX shares. JPMorgan Chase & Co. cut their price target on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a report on Tuesday, October 29th. Oppenheimer reduced their target price on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. Needham & Company LLC lowered their price target on TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday, October 29th. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Finally, Piper Sandler reissued an “overweight” rating and issued a $180.00 target price on shares of TransMedics Group in a research report on Tuesday, October 29th. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, TransMedics Group currently has a consensus rating of “Buy” and a consensus target price of $144.80.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the transaction, the insider now owns 21,105 shares of the company’s stock, valued at $3,714,902.10. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Nicholas Corcoran sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the transaction, the insider now owns 21,105 shares of the company’s stock, valued at $3,714,902.10. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 36,958 shares of company stock worth $5,230,528 in the last ninety days. 7.00% of the stock is owned by insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.